All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, August 19, 2022
Home » Blogs » BioWorld Perspectives » What Global Financial Crisis? Capital Markets Back Biotechs

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

What Global Financial Crisis? Capital Markets Back Biotechs

Oct. 3, 2012
By Peter Winter
No Comments

It is that time of year again when we take the pulse of the industry at the close of the third quarter. Overall we find that it is performing well, more so for public biotechs than private ones. Despite the continuing turbulence in the global capital markets investors have had no qualms about backing the biotech sector.

The average increase in the stock values of the 231 public biotech companies tracked by the BioWorld Stock Report is up 38 percent year-to-date. The third quarter was particularly hot for biotechs with their collective stock values soaring by an average of over 12 percent compared with a 4 percent increase in the Dow Jones Industrial Average and a 6 percent increase in the NASDAQ Composite index.

The welcoming capital markets allowed biotechs to take advantage of their increased stock values to conduct follow-on financing. In the third quarter more than $2.8 billion was raised through public offerings compared to only $507 million in the comparable period in 2011, according to data compiled from BioWorld Snapshots.

The same trend held true for private placements such as registered direct offerings, rights offerings and at-the-market deals with public biotechs raising $1.97 billion in the third quarter of 2012 from these financing vehicles well over double the $821 million raised during Q3 2011.

The increased public financing in the third quarter helped biotech companies collectively raise $5.91 billion, an amount that was 111 percent more than the $2.75 billion raised in the third quarter of 2011.

According to statistics compiled by BioWorld Insight, the biotech sector is making up for a very sluggish start to the year with a total of $13.8 billion raised in the first three quarters. This now compares more favorably to the $16.1 billion raised in the same period of 2011, which, by any standards, was considered a very hot year for biotech financing.

On the venture capital front our analysis confirms that deal making for private biotech companies still remains extremely challenging. At the three-quarter post of 2012 global private biotechs had raised $2.35 billion, 33 percent less than the $3.51 billion raised in the same period of 2011.

The public U.S. markets continue to offer an alternative for later-round companies looking for funding. Although the appetite for biotech IPOs cooled off in the third quarter with no deals taking place in August and September, eight companies have gone public year-to-date, comparable to the 9 deals we saw at this time last year. This amounts generated from the 2012 IPO transactions was $536 million compared to $503 raised in 2011.

Given the positive capital markets at the present time it is likely that we will see a flurry of companies, currently on the IPO runway, price their public offerings. According to BioWorld Snapshots there are nine biotech companies that are on the IPO runway.

For full analysis of the performance of the biotech sector in the third quarter read the Oct. 8, 2012 cover story in BioWorld Insight.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 19, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 19, 2022.
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
  • TPOXX

    Siga leads monkeypox antiviral research, amid lack of interest from big pharma

    BioWorld
    After declarations from the World Health Organization and the U.S. government that monkeypox is a public health emergency, attention is turning to the pharma...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing